Reconsidering REMS Mandate May Improve CAR T-Cell Therapy Accessibility von ONCOLOGY Staff

Volltext

FDA Approval Alert: Epcoritamab in Relapsed/Refractory Follicular Lymphoma von ONCOLOGY Staff

Volltext

FDA Approval Alert: Liso-Cel in Relapsed/Refractory Mantle Cell Lymphoma von ONCOLOGY Staff

Volltext

Recap: Available Treatment Options in Transplant-Eligible Multiple Myeloma von ONCOLOGY Staff

Volltext

Recap: Experts Discuss Treatment Methodologies in RCC von ONCOLOGY Staff

Volltext

Multidisciplinary Care Is Imperative to the Future of Breast Cancer Treatment von ONCOLOGY Staff

Volltext

Two months of radiation oncology in the heart of Italian "red zone" during COVID-19 pandemic: paving a safe path over thin ice von Buglione, Michela, Spiazzi, Luigi, Guerini, Andrea Emanuele, Barbera, Fernando, Pasinetti, Nadia, Pegurri, Ludovica, Triggiani, Luca, Tomasini, Davide, Greco, Diana, Costantino, Gianluca, Bragaglio, Alessandra, Bonometti, Nadia, Liccioli, Mara, Mascaro, Lorella, Alongi, Filippo, Magrini, Stefano Maria

Volltext

T-DXd Has Revolutionized the Standard of Care in Breast Cancer von ONCOLOGY Staff

Volltext

NEW POTENTIAL FRONTLINE STANDARDS FOR RCC ARE SPOTLIGHTED AT GENITOURINARY CANCERS SYMPOSIUM von Moore, Kathleen

Volltext

Advancement Continues in 'Go-to' Strategies for Gynecologic Cancer von ONCOLOGY Staff

Volltext

FDA Approves Imaging Agent Designed to Target Tumors in Lung Cancer von ONCOLOGY Staff

Volltext

Researchers Seek More Treatment Options for Gastrointestinal Cancer von ONCOLOGY Staff

Volltext

A phase 2 study using ipilimumab, nivolumab, and trabectedin for previously untreated metastatic soft tissue sarcoma von Gordon, Erlinda Maria, Chua, Victoria S., Kim, Ted T., Chawla, Neal Shiv, Brigham, Don Arlen, Bhuiyan, Ishrat, Agulnik, Mark, Chow, Warren Allen, Chawla, Sant P.

Volltext

Quadruplet Therapy May Be the New Frontline SOC in Multiple Myeloma von Fonseca, Rafael, Costa, Luciano, Dhakal, Binod, Voorhees, Peter, Lee, Hans, Kumar, Shaji

Volltext

Inpatient vs Outpatient Use of Teclistamab in Multiple Myeloma von ONCOLOGY Staff

Volltext

Amivantamab vs Mobocertinib in Exon 20 NSCLC von Spira, Alexander I, Bestvina, Christine, Sabari, Joshua K, Das, Millie, Nagasaka, Misako

Volltext

Determining Administration of BCMA, T-Cell Engagers in R/R Multiple Myeloma von Mikhael, Joseph, Baljevic, Muhamed, Landgren, C. Ola, Valdes, Cesar Rodriquez, Usmani, Saad Z, Callander, Natalie, Richter, Joshua

Volltext

Ruxolitinib Stands Out Among JAK2 Inhibitors for Myelofibrosis von Targeted Oncology Staff

Volltext

The Current and Inevitable Expansion of AI in Oncology von Targeted Oncology Staff

Volltext

Evaluation for Bleeding Disorders in Suspected Child Abuse von Anderst, James, Carpenter, Shannon L., Abshire, Thomas C., Killough, Emily, Mendonca, Eneida A., Downs, Stephen M., Wetmore, Cynthia, Allen, Carl, Dickens, David, Harper, James, Rogers, Zora R., Jain, Juhi, Warwick, Anne, Yates, Amber, Hord, Jeffrey, Lipton, Jeffrey, Wilson, Hope, Kirkwood, Suzanne, Haney, Suzanne B., Asnes, Andrea Gottsegen, Gavril, Amy R., Girardet, Rebecca Greenlee, Heavilin, Nancy, Gilmartin, Amanda Bird Hoffert, Laskey, Antoinette, Messner, Stephen A., Mohr, Bethany Anne, Nienow, Shalon Marie, Rosado, Norell, Idzerda, Sheila M., Legano, Lori A., Raj, Anish, Sirotnak, Andrew P., Forkey, Heather C., Keeshin, Brooks, Matjasko, Jennifer, Edward, Heather, Chavdar, Müge, Di Paola, Jorge, Leavey, Patrick, Graham, Doug, Hastings, Caroline, Hijiya, Nobuko, Matthews, Dana, Pace, Betty, Velez, Maria C., Wechsler, Dan, Billett, Amy, Stork, Linda, Hooker, Ryan

Volltext